6576.TWO Foresee Pharmaceuticals Co Ltd

Healthcare Pharmaceuticals Taiwan OTC Exchange
71.90 TWD
Close of Nov 6, 2026
67.30 93.70
Market cap
TWD 11.3B
P/E
513.6x
P/B
9.04x
ROE
44.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6576.TWO undervalued?

Graham number

The Graham number of Foresee Pharmaceuticals Co Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Foresee Pharmaceuticals Co Ltd fundamental analysis

No fundamental analysis for Foresee Pharmaceuticals Co Ltd yet.

Foresee Pharmaceuticals Co Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Foresee Pharmaceuticals Co Ltd

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for t…

Full company profile